Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Table 4

Clinical trials with bevacizumab as second-line treatment.

Study	No. of patients	Design	Treatment	Primary end point	Results
TML [70]	820	Phase 3, open-label, RCT	CTx versus bevacizumab + CTx	OS	HR, 0.81; 95% CI, 0.69–0.94	0.0062
BEBYP [71]	185	Phase III, RCT	FOLFIRI or mFOLFOX6 versus FOLFIRI or mFOLFOX6 + bevacizumab	PFS	HR, 0.66; 95% CI, 0.49–0.90	0.0072
ECOG E3200 [72]	829	Phase III, open-label, RCT	FOLFOX4 + bevacizumab versus FOLFOX4 versus bevacizumab	OS	HR, 0.75	0.0011

No.: number; PFS: progression-free survival; CI: confidence interval; RCT: randomized controlled trial; HR: hazard ratio; OS: overall survival; CTx: chemotherapy.